Drug Trial Radar · NCT05200364
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
58
Actual
Start
Mar 22, 2022
Primary completion
Jun 1, 2025
Study completion Jun 1, 2025
Sponsor
- Lead sponsor
- Sutro Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.
Conditions
- Ovarian Cancer
- Ovarian Carcinoma
- Ovary Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
Interventions
STRO-002Drug
intravenous antibody drug conjugate
BevacizumabDrug
anti-VEGF agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 - Safety and tolerability of STRO-002/bevacizumab as a combination therapyTime frame: From baseline through end of study (approximately 24 months)
- Part 1 - Determine the recommended phase 2 dose (RP2D) of STRO-002/bevacizumabTime frame: From baseline through end of study (approximately 24 months)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of South Florida,
Tampa, Florida
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
Tennessee Oncology
Nashville, Tennessee
Virginia Cancer Specialists
Fairfax, Virginia
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.